1 / 13

Hepatitis C+ Recipients: Considerations for Exclusion

Hepatitis C+ Recipients: Considerations for Exclusion. Emily A. Blumberg, M.D. Hepatitis C+ Recipients and Transplantation. Decreased long term patient survival Decreased long term graft function Increased risk of chronic liver disease Increased risk of renal disease

ismet
Télécharger la présentation

Hepatitis C+ Recipients: Considerations for Exclusion

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hepatitis C+ Recipients: Considerations for Exclusion Emily A. Blumberg, M.D.

  2. Hepatitis C+ Recipients and Transplantation • Decreased long term patient survival • Decreased long term graft function • Increased risk of chronic liver disease • Increased risk of renal disease • Impaired immunological function • Increased risk of post transplant diabetes mellitus

  3. Kidney Transplant Survival Based on HCV Status Legendre, et al. Transplantation 1998

  4. Graft Survival in Kidney Transplant Recipients Mathurin, et al. Hepatology 1999

  5. Outcome of HCV+ Recipients After OLT • Median time to cirrhosis 12 years • 28% cirrhotic at 5 years • Decompensation < 1 year, typically with ascites • Decompensation associated with >50% 1 year mortality • Risk factors for fibrosis post transplant • HCV RNA level at OLT • Immunosuppressive regimen (MMF, Rejection Rx) • Year of transplantation

  6. Impact of HCV on Liver Disease in Kidney Transplantation Hanafusa, et al, Transplantation 1998

  7. Interferon Treatment of HCV Post Transplant • Poorly tolerated • Limited efficacy • Potential increased risk of rejection • Potential risk of renal failure

  8. Post Transplant Nephropathy and HCV+ Recipients • HCV is a risk factor for de novo immune mediated post transplant nephropathy • Membranoproliferative GN • Membranous GN • Changes may be seen in first 4 months • Patients with autoimmune renal disease may have decreased progression of hepatic disease

  9. Probability of Death Due to Sepsis in Renal Transplant Patients Pereira, et al. Transplantation 1995

  10. In vitro Proliferative Responses in Renal Transplant Patients Khanna, et al. Transplant 2001, abstr542

  11. Impact of HCV on Post Transplant Diabetes Mellitus Baid, et al Transplant 2001 abstract 86

  12. Impact of HCV on HIV Infection • Increased mortality • Increased risk of opportunistic infection • Impaired/delayed CD4 recovery

  13. HCV + Recipients • Inclusion of HCV coinfected pts for OLT if we want to minimize harm and improve outcome? • Does the high rate of HCV infection justify inclusion? • Will liver bx pre kidney tx be adequate to protect subjects from liver disease? • Should HCV treatment decisions be left to pt and PCP?

More Related